Context Therapeutics Inc. - 8-K Filing
Context Therapeutics Inc. increased its authorized common stock from 200 million to 300 million shares, approved by shareholders at the June 24, 2026 annual meeting with a vote of approximately 79% in favor. Shareholders also elected seven directors and ratified CohnReznick LLP as their independent auditor. (Items: 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $CNTX